Can a New Blood Test Revolutionize Cancer Treatment?
"Scientists Develop Innovative Method for Detecting Apoptotic Circulating Tumor Cells, Promising Earlier Insights into Treatment Effectiveness."
Cancer remains one of the most formidable health challenges globally, with metastasis—the spread of cancer cells from the primary tumor to distant sites—being a primary cause of cancer-related deaths. The ability to monitor and understand the behavior of circulating tumor cells (CTCs) is vital in assessing cancer progression and treatment effectiveness.
Circulating tumor cells (CTCs) hold immense potential as prognostic markers for metastatic development and therapeutic efficacy. However, only viable CTCs that survive in the bloodstream can initiate distant metastases. Monitoring the proportion of CTCs undergoing apoptosis (programmed cell death) is critical.
A new study introduces an innovative approach using multicolor in vivo flow cytometry (FFC) to characterize the apoptosis status of CTCs. This method enables real-time identification and enumeration of apoptotic CTCs directly in the bloodstream, promising more effective cancer treatment monitoring and personalized therapies.
Circulating Tumor Cells and Metastasis
Metastasis, in which tumor cells travel through the bloodstream from the original site to other parts of the body, is identified as the primary reason for high cancer mortality rates. A 2024 review describes circulating tumor cells (CTCs) as part of this process. A 2025 study notes that cell death among tumor and stromal cells is widespread during tumor progression, particularly after cytotoxic therapy, and refers to clinical observations linking high levels of apoptotic cells with poorer outcomes.
A Long History of Cancer Research
Cancer has been described in records from ancient Egyptian and Greek civilizations, reflecting a medical history spanning millennia. A historical review says that early treatment relied largely on radical surgery and cautery, which were not very effective. Later milestones include advances in surgery, radiation therapy, and chemotherapy, while newer treatments reflect growing understanding of cancer. A 2016 chapter specifically reviews the history of research on circulating tumor cells (CTCs) and the opportunities and challenges of using them in diagnosis and treatment decisions.
Unlocking the Potential of In Vivo Fluorescence Flow Cytometry
In vivo fluorescence flow cytometry (FFC) is emerging as a powerful tool for real-time monitoring of cellular dynamics in living organisms. Unlike traditional methods that require removing cells from their natural environment, FFC allows for the direct observation and quantification of cells within the bloodstream. This capability is particularly valuable for studying circulating tumor cells (CTCs), which play a crucial role in cancer metastasis.
- Real-Time Monitoring: Offers continuous observation of CTC behavior in their natural environment.
- Improved Accuracy: Provides a more precise assessment of treatment effectiveness by quantifying apoptotic CTCs.
- Personalized Therapy: Enables tailored treatment strategies based on individual patient responses.
- Reduced Artifacts: Minimizes the risk of altering CTC characteristics during sample preparation.
New Findings and CTC Review
A July 2025 study reported that circulating apoptotic cells robustly enhanced tumor-cell metastasis to the lungs in intravenous metastasis models. In those models, apoptotic cells—but not cells dying by other mechanisms—supported CTC survival after the cells became arrested in lung blood vessels. Separately, a 2025 review describes CTCs as cancer cells shed into the bloodstream and says that technological advances may expand CTC-based biomarkers, although rare-cell capture has limited their utility. Another review describes cancer-cell plasticity, including epithelial, mesenchymal, and hybrid phenotypes, and reports that some cells can acquire stem cell-like properties linked to self-renewal and tumor initiation.
Small Cohorts and Model Limitations
Evidence about CTCs and apoptosis has important limitations. A prospective observational study of metastatic breast cancer included only 52 patients and described its analysis as exploratory, with limited statistical power. A colorectal cancer pilot study examined 22 patients; its authors said larger cohorts were needed to corroborate the association they observed between apoptotic CTCs, CTC debris, debris, and liver metastasis. The 2025 intravenous metastasis study also notes that its model cannot show effects at other stages of metastasis and does not closely reproduce some physiological features of human patients.
The Future of Cancer Monitoring
The introduction of multicolor FFC marks a significant advancement in cancer monitoring. By providing real-time data on apoptotic CTCs, this technology paves the way for more personalized and effective cancer treatments. As research progresses, integrating additional markers and photoacoustic modules could further enhance the capabilities of FFC, making it an indispensable tool in the fight against cancer.
Recovery and Unanswered Questions
An FDA review memorandum reports an average recovery of 93% over the tested CTC range, as derived from regression analysis. Separately, a review notes that cell death among tumor and stromal cells is widespread during tumor progression and especially after cytotoxic therapy. It also says that, although clinical observations link high levels of apoptotic cells with poorer outcomes, the physiological effects of dying cells on tumor progression remain incompletely understood.
Monitoring Challenges and False Negatives
The FDA warns that a falsely low cancer-cell measurement could lead to missed disease progression or recurrence, or to a false indication that therapy is working. A 2022 review says CTCs obtained through liquid biopsy can provide tumor DNA, RNA, and protein information that may aid diagnosis, prognosis, and treatment, while noting that tumors' mutational and phenotypic landscape is dynamic. A 2026 review describes CTCs as biomarkers for real-time monitoring and examines metabolic and epigenetic reprogramming that may help them survive, disseminate, and resist therapy. Another review says drug development and clinical efficacy studies have largely focused on tumor-cell growth, potentially overlooking circulating or disseminated tumor cells.